A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer
Clinical trial NCT05026905 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05026905
- Sponsor
- National Health Research Institutes, Taiwan
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-28
- Primary completion
- 2027-12-01
- Enrollment
- 66
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.